294 related articles for article (PubMed ID: 33704360)
1. NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
Bastia E; Toris CB; Brambilla S; Galli C; Almirante N; Bergamini MVW; Masini E; Sgambellone S; Unser AM; Ahmed F; Torrejon KY; Navratil T; Impagnatiello F
Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):17. PubMed ID: 33704360
[TBL] [Abstract][Full Text] [Related]
2. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
[TBL] [Abstract][Full Text] [Related]
3. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
Stankowska DL; Millar JC; Kodati B; Behera S; Chaphalkar RM; Nguyen T; Nguyen KT; Krishnamoorthy RR; Ellis DZ; Acharya S
Mol Vis; 2021; 27():37-49. PubMed ID: 33633438
[TBL] [Abstract][Full Text] [Related]
4. NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs.
Galli C; Bastia E; Hubatsch DA; Toris C; Fan S; Unser A; Ahmed F; Torrejon KY; Impagnatiello F
J Ocul Pharmacol Ther; 2023 Dec; ():. PubMed ID: 38088745
[No Abstract] [Full Text] [Related]
5. NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Bastia E; Toris C; Bukowski JM; Brambilla S; Galli C; Almirante N; Bergamini MVW; Lucarini L; Navratil T; Impagnatiello F
J Ocul Pharmacol Ther; 2021 May; 37(4):215-222. PubMed ID: 33595367
[No Abstract] [Full Text] [Related]
6. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
7. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
8. A digoxin derivative that potently reduces intraocular pressure: efficacy and mechanism of action in different animal models.
Barathi VA; Katz A; Chaudhary S; Li HL; Tal DM; Marcovich A; Do CW; Karlish SJD
Am J Physiol Cell Physiol; 2024 May; 326(5):C1505-C1519. PubMed ID: 38557355
[TBL] [Abstract][Full Text] [Related]
9. ID1 and ID3 are Negative Regulators of TGFβ2-Induced Ocular Hypertension and Compromised Aqueous Humor Outflow Facility in Mice.
Mody AA; Millar JC; Clark AF
Invest Ophthalmol Vis Sci; 2021 May; 62(6):3. PubMed ID: 33938911
[TBL] [Abstract][Full Text] [Related]
10. Effects of topical TGF-β1, TGF-β2, ATX, and LPA on IOP elevation and regulation of the conventional aqueous humor outflow pathway.
Nakamura N; Yamagishi R; Honjo M; Igarashi N; Shimizu S; Aihara M
Mol Vis; 2021; 27():61-77. PubMed ID: 33633440
[TBL] [Abstract][Full Text] [Related]
11. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
12. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
Prasanna G; Ferrara L; Adams C; Ehara T; Li B; Yang L; Xiang C; Ng CTH; Kim S; Towler C; Topley T; McAllister C; Ghosh M; Newton R; Stacy R; Rice DS; Mogi M
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1704-1716. PubMed ID: 29610853
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
[TBL] [Abstract][Full Text] [Related]
15. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
[TBL] [Abstract][Full Text] [Related]
16. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
Cavet ME; DeCory HH
J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
[TBL] [Abstract][Full Text] [Related]
17. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice.
Millar JC; Savinainen A; Josiah S; Pang IH
Exp Eye Res; 2019 Nov; 188():107763. PubMed ID: 31421135
[TBL] [Abstract][Full Text] [Related]
18. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
19. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
Nilsson SF; Drecoll E; Lütjen-Drecoll E; Toris CB; Krauss AH; Kharlamb A; Nieves A; Guerra T; Woodward DF
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
[TBL] [Abstract][Full Text] [Related]
20. Effects of Toll-Like Receptor 4 Inhibition on Transforming Growth Factor-β2 Signaling in the Human Trabecular Meshwork.
Sharma TP; Curry S; McDowell CM
J Ocul Pharmacol Ther; 2020 Apr; 36(3):170-178. PubMed ID: 31834824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
